Avenda Health, an AI healthcare company focused on creating the future of personalized prostate cancer care, has announced that its FDA cleared prostate cancer management platform, Unfold AI™, is now being used in a commercial setting at a prestigious U.S. research hospital. The platform combines patient-specific data from prostate imaging, biopsies, and pathology with deep-learning algorithms, resulting in a unique cancer estimation map that visualizes the cancer location.
Dr. Leonard Marks, co-founder and Chief Medical Officer of Avenda Health, said, “This is a major step forward for the prostate cancer community, and we are beyond thrilled to see a decade of hard work and research pay off. Our mission at Avenda Health is to create a better quality of life for prostate cancer patients and to give urologists a clearer view of the cancer so we can better treat our patients. Unfold AI will improve clinical care and decision making.”
Unfold AI has shown to be highly effective during clinical trials, with guidance from the platform causing physicians to change their treatment recommendations in 28% of the cases, many times towards more localized treatment. The platform provides multiple treatment options based on its results, including active surveillance, whole gland treatments like radical prostatectomy and radiation therapy, or soft tissue laser ablation using Avenda Health’s FocalPoint device.
The company is committed to making this cutting-edge technology available to all physicians treating prostate cancer patients, aiming to improve outcomes, preserve quality of life, and create a new standard of cancer care. Unfold AI received 510(k) clearance from the U.S. FDA in December 2022. For more information on Avenda Health and its groundbreaking technology, visit avendahealth.com.